475 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
cb-011 Plasma Cell Myeloma	Caribou Biosciences, Inc.	P1	CC (41)
cd19/bcma-targeted car-t cells Plasma Cell Myeloma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1	CC (41)
hlx15-sc-rd Plasma Cell Myeloma	Shanghai Henlius Biotech	P1	CC (41)
ici201 Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	P1	CC (41)
Isb 2001 Plasma Cell Myeloma	Ichnos Sciences SA	P1	CC (41)
Jnj-87562761 Plasma Cell Myeloma	Janssen Research & Development, LLC	P1	CC (41)
Lcar-Bcdr Cells Product Plasma Cell Myeloma	Weijun Fu	P1	CC (41)
Lucar-B68 Cells Product Plasma Cell Myeloma	Second Affiliated Hospital of Xi'an Jiaotong University	P1	CC (41)
Mrna-2736 Plasma Cell Myeloma	ModernaTX, Inc.	P1	CC (41)
Pavurutamab Plasma Cell Myeloma	Amgen	P1	CC (41)
Pmcc-Coe-Kma Plasma Cell Myeloma	Peter MacCallum Cancer Centre, Australia	P1	CC (41)
ro7851624 Plasma Cell Myeloma	Genentech, Inc.	P1	CC (41)
sar445514 Plasma Cell Myeloma	Sanofi	P1	CC (41)
sim0500 Plasma Cell Myeloma	Jiangsu Simcere Pharmaceutical Co., Ltd.	P1	CC (41)
Ykst02 Plasma Cell Myeloma	Excyte Biopharma Ltd	P1	CC (41)
yts104 cells Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (41)
1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer Plasma Cell Myeloma	Pfizer	P1	CC (40)
Anti-Fcrl5 Car-T Plasma Cell Myeloma	Xuzhou Medical University	P1/2	CC (40)
April-Baff-Bicephali Car-T Cells Plasma Cell Myeloma	Xuzhou Medical University	P1/2	CC (40)
azd0305 Plasma Cell Myeloma	AstraZeneca	P1/2	CC (40)
B-Cell Maturation Antigen Directed Chimeric Antigen Receptor -T Cell Plasma Cell Myeloma	Bioray Laboratories	P1/2	CC (40)
Bcma/Gprc5D Car-T Cells Plasma Cell Myeloma	Essen Biotech	P1/2	CC (40)
Bcma Targeted Prime Car-T Cells Plasma Cell Myeloma	Chongqing Precision Biotech Co., Ltd	P1/2	CC (40)
Belantamab Plasma Cell Myeloma	GlaxoSmithKline	P1/2	CC (40)
Car.70/Il15-Transduced Cb-Nk Cells Plasma Cell Myeloma	M.D. Anderson Cancer Center	P1/2	CC (40)
Car-Bcma Plasma Cell Myeloma	Sheba Medical Center	P1/2	CC (40)
Cart-138/Bcma/19/More Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	P1/2	CC (40)
Cart-138 Cells Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	P1/2	CC (40)
Cartemis-1 Plasma Cell Myeloma	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	P1/2	CC (40)
ct071 Plasma Cell Myeloma	CARsgen Therapeutics Co., Ltd.	P1/2	CC (40)
Dostarlimab Plasma Cell Myeloma	GlaxoSmithKline	P1/2	CC (40)
Enzomenib Plasma Cell Myeloma	Sumitomo Pharma America, Inc.	P1/2	CC (40)
Ezobresib Plasma Cell Myeloma	Bristol-Myers Squibb	P1/2	CC (40)
Feladilimab Plasma Cell Myeloma	GlaxoSmithKline	P1/2	CC (40)
Gilteritinib Plasma Cell Myeloma	Sumitomo Pharma America, Inc.	P1/2	CC (40)
Gsk 3174998 Plasma Cell Myeloma	GlaxoSmithKline	P1/2	CC (40)
Idp-023 Plasma Cell Myeloma	Indapta Therapeutics, INC.	P1/2	CC (40)
kq-2003 car t-cells Plasma Cell Myeloma	Novatim Immune Therapeutics (Zhejiang) Co., Ltd.	P1/2	CC (40)
Lisaftoclax Plasma Cell Myeloma	Ascentage Pharma Group Inc.	P1/2	CC (40)
Nanobody-Based Biepitope Bcma-Targeting Car-T Cells Plasma Cell Myeloma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1/2	CC (40)
Osteodex Plasma Cell Myeloma	DexTech Medical AB	P1/2	CC (40)
Rock2 Inhibitor Kd025 Plasma Cell Myeloma	M.D. Anderson Cancer Center	P1/2	CC (40)
Slamf7 Fpbmc Plasma Cell Myeloma	University of Virginia	P1/2	CC (40)
Sotatercept Plasma Cell Myeloma	Rebecca Silbermann	P2	CC (40)
Sti-6129 Plasma Cell Myeloma	Zhejiang ACEA Pharmaceutical Co. Ltd.	P1/2	CC (40)
Syhx1903 Plasma Cell Myeloma	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1/2	CC (40)
Tazemetostat Plasma Cell Myeloma	Bristol-Myers Squibb	P1/2	CC (40)
tg01 Plasma Cell Myeloma	Oslo University Hospital	P1/2	CC (40)
Zevor-Cel Plasma Cell Myeloma	CARsgen Therapeutics Co., Ltd.	P1/2	CC (40)
Zilurgisertib Plasma Cell Myeloma	Incyte Corporation	P1/2	CC (40)

Showing 301 to 350 of 475 assets

PreviousPage 7 of 10Next